Saturday, October 3, 2026

EUR/JPY Bullish Momentum: 0.59% Up Since The Last Session

ViaNews Editorial Team

January 6, 2021

EUR/JPY Bullish Momentum: 0.59% Up Since The Last Session

EUR/JPY is currently on bullish momentum. At 08:30 EST EST on Wednesday, 6 January, EUR/JPY is at ¥127.0270, 0.59% up since the last session's close.

EUR/JPY Range

EUR/JPY is 0.775% up from its last session low of ¥126.0500 and 0.38% up from its last session high of ¥126.5460.

Over the last three sessions, EUR/JPY's higher value was ¥126.7820 and the lower value was ¥125.2200.

Over the last seven sessions, EUR/JPY's higher value was ¥127.2100 and the lower value was ¥125.2200.

Over the last month, EUR/JPY's higher value was ¥127.2100 and the lower value was ¥125.2200.

EUR/JPY's yearly highs and lows, it's 10.984% up from its 52-week low and 0.144% down from its 52-week high.

Volatility

EUR/JPY's last day, last week, and last month's average volatility was a negative 0.0900%, a negative 0.0580%, and a positive 0.0029%, respectively.

EUR/JPY's last day, last week, and last month's high and low average amplitude percentage was 0.3900%, 0.6220%, and 0.5024%, respectively.

Last news about EUR/JPY

Eur/usd, eur/jpy rates eyeing euro-area inflation and PMI figures. According to DailyFX on Monday, 4 January, "The pattern's implied measured move suggesting that EUR/JPY could climb as much as 2% from current levels to test the 129.00 mark.", "Recent changes in sentiment warn that the current EUR/JPY price trend may soon reverse lower despite the fact traders remain net-short."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com
EUR/JPY Bullish Momentum: 0.59% Up Since The Last Session | Via News